Table I.
Characteristics of study subjects negative and positive for HCV RNA.
| Characteristics | HCV RNA (−) (n=19, 43.2%) | HCV RNA (+) (n=25, 56.8%) | P-valuea |
|---|---|---|---|
| Age (years) | 45 (30–58) | 43 (30–68) | 0.7130 |
| Hemophilia A/B (%) | 16 (84.2)/3 (15.8) | 23 (92.0)/2 (8.0) | 0.7437 |
| non-LC/LC (%) | 14 (73.7)/5 (26.3) | 10 (40.0)/15 (60.0) | 0.0552 |
| Prior infection with HBVb (−/+) (%) | 4 (21.1)/15 (78.9) | 9 (36.0)/16 (64.0) | 0.4575 |
| HCV RNA (log IU/ml) | N.D.c | 6.3 (<1.2–7.5) | N.D. |
| HIV RNA (−/+) (%) | 16 (84.2)/3 (15.8) | 21 (84.0)/4 (16.0) | 0.6913 |
| WBC (/mm3) | 4,900 (3,200–8,800) | 3,900 (1,800–8600) | 0.0329 |
| CD4 number (/ml) | 502 (219–1081) | 359 (143–544) | 0.0041 |
| CD4% (%) | 29.7 (18.9–44.5) | 29.9 (13.3–46.5) | 0.1694 |
| Hb (g/dl) | 15.0 (11.3–17.1) | 14.5 (8.5–17.4) | 0.6351 |
| Plt (×104/mm3) | 17.0 (11.1–34.9) | 12.2 (4.4–33.1) | 0.0019 |
| PT (%) | 93 (63–116) | 81 (43–112) | 0.0215 |
| T. bil (mg/dl) | 0.9 (0.4–3.4) | 1.0 (0.4–4.3) | 0.9810 |
| AST (IU/l) | 30 (17–45) | 38 (18–173) | 0.0091 |
| ALT (IU/l) | 29 (11–74) | 41 (8–183) | 0.1150 |
| Cr (mg/dl) | 0.72 (0.46–1.19) | 0.79 (0.52–10.3) | 0.5530 |
| eGFR (ml/min/1.73 m2) | 88.9 (53.1–157.4) | 85.0 (4.6–138.6) | 0.3139 |
| AFP (ng/dl) | 2.7 (1.5–9.2) | 5.6 (1.5–654.4) | 0.0229 |
| HbA1c (%) | 5.0 (4.3–6.2) | 5.1 (4.4–7.6) | 0.2119 |
| APRI | 0.53 (0.18–0.91) | 1.08 (0.28–3.30) | 0.0001 |
| Fib4 score | 1.46 (0.53–3.44) | 3.27 (0.62–6.69) | 0.0040 |
| IL28Bd (major/minor) (%) | 10 (90.9)/1 (9.1) | 10 (76.9)/3 (23.1) | 0.7140 |
| Previous IFN therapy (−/+) (%) | 5 (26.3)/14 (73.7) | 10 (40.0)/15 (60.0) | 0.5303 |
| Anti-HIV therapy | 0.9321 | ||
| PI plus 2-NRTI | 2 (10.5) | 2 (8.0) | |
| Boosted PI plus 2-NRTI | 6 (31.6) | 9 (36.0) | |
| Boosted PI plus INSTI | 0 (0) | 2 (8.0) | |
| Boosted PI plus 2-NRTI and INSTI | 2 (10.5) | 2 (8.0) | |
| INSTI plus 2-NRTI | 5 (26.3) | 2 (8.0) | |
| NNRTI plus 2-NRTI | 0 (0) | 4 (16.0) | |
| Others | 4 (21.1) | 4 (16.0) | |
| TDF containing regimen (−/+) (%) | 11 (57.9)/8 42.1) | 14 (56.0)/11 (44.0) | 0.8559 |
LC, liver cirrhosis; HBV, hepatitis B virus; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; PT, prothrombin time; T bil, total bilirubin; AST, Aspartate Aminotransferase; ALT, alanine transaminase; Cr, creatinine; eGFR, estimated glomerular filtration rate; AFP, alpha-fetoprotein; HbA1c, glycated hemoglobin A1c; APRI, aspartate transaminase (AST)-platelet ratio index; Fib4 score, Fibrosis-4 score; IL28B, interleukin 28 B; IFN, interferon; PI, protease inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; TDF, tenofovir disoproxil fumarate. Median and range presented, unless otherwise indicated.
P-value was calculated by statistical analysis between HCV non-LC and LC subjects.
Positive for ‘Prior infection with HBV’ indicates positive for any one among HBs antigen, HBs antibody, HBc antibody, and HBe antibody.
N.D. indicated non-detectable. dIL28B indicated IL28B single-nucleotide polymorphisms (rs8099917).